24.86
price up icon0.77%   0.19
after-market After Hours: 24.86
loading
Pacira Biosciences Inc stock is traded at $24.86, with a volume of 331.15K. It is up +0.77% in the last 24 hours and down -3.94% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$24.67
Open:
$24.6
24h Volume:
331.15K
Relative Volume:
0.61
Market Cap:
$990.97M
Revenue:
$734.86M
Net Income/Loss:
$5.14M
P/E Ratio:
198.88
EPS:
0.125
Net Cash Flow:
$132.71M
1W Performance:
+6.97%
1M Performance:
-3.94%
6M Performance:
+6.19%
1Y Performance:
-3.79%
1-Day Range:
Value
$24.49
$25.04
1-Week Range:
Value
$23.32
$25.04
52-Week Range:
Value
$18.80
$27.66

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name
Name
Pacira Biosciences Inc
Name
Phone
650-242-8052
Name
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Name
Employee
829
Name
Twitter
Name
Next Earnings Date
2026-08-04
Name
Latest SEC Filings
Name
PCRX's Discussions on Twitter

Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PCRX icon
PCRX
Pacira Biosciences Inc
24.86 949.91M 734.86M 5.14M 132.71M 0.125
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.24 57.90B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
10.16 43.41B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
36.93 42.89B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
77.17 31.00B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
512.88 22.35B 3.17B 1.29B 1.01B 27.09

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-25 Initiated Barclays Equal Weight
Nov-17-25 Initiated H.C. Wainwright Buy
Jul-25-25 Upgrade Truist Hold → Buy
Jan-30-25 Upgrade Truist Sell → Hold
Aug-13-24 Downgrade Truist Buy → Sell
Aug-12-24 Downgrade JP Morgan Overweight → Underweight
Aug-12-24 Downgrade Piper Sandler Overweight → Neutral
Aug-12-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-12-24 Downgrade Raymond James Outperform → Mkt Perform
Jul-03-24 Downgrade Barclays Overweight → Equal Weight
Mar-07-24 Resumed JP Morgan Overweight
Dec-20-23 Initiated Raymond James Outperform
Aug-03-23 Upgrade TD Cowen Market Perform → Outperform
Jan-31-23 Resumed Wedbush Outperform
Oct-21-22 Resumed Jefferies Buy
Jan-03-22 Resumed JP Morgan Overweight
Jul-26-21 Upgrade JP Morgan Neutral → Overweight
Apr-21-21 Resumed JP Morgan Neutral
Apr-09-21 Initiated Berenberg Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Feb-11-21 Downgrade Northland Capital Outperform → Market Perform
Jan-21-21 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-21-20 Upgrade Northland Capital Market Perform → Outperform
Jul-06-20 Reiterated Needham Buy
May-27-20 Initiated Guggenheim Neutral
Apr-07-20 Initiated Northland Capital Outperform
Mar-20-20 Upgrade SVB Leerink Mkt Perform → Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-24-20 Initiated SunTrust Buy
Jan-23-20 Initiated SunTrust Buy
Nov-06-19 Initiated BTIG Research Buy
Jun-11-19 Initiated Barclays Overweight
May-06-19 Upgrade Mizuho Underperform → Neutral
May-02-19 Upgrade Stifel Sell → Hold
Feb-01-19 Downgrade Mizuho Neutral → Underperform
Aug-06-18 Downgrade BofA/Merrill Buy → Neutral
Apr-09-18 Reiterated H.C. Wainwright Buy
Mar-21-18 Reiterated Mizuho Neutral
Feb-16-18 Downgrade Needham Buy → Hold
Jan-19-18 Initiated Seaport Global Securities Buy
Jan-04-18 Reiterated Canaccord Genuity Buy
Jan-03-18 Initiated Leerink Partners Mkt Perform
View All

Pacira Biosciences Inc Stock (PCRX) Latest News

pulisher
Aug 21, 2026

Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus

Aug 21, 2026
pulisher
Aug 20, 2026

Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 20, 2026
pulisher
Aug 19, 2026

Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - Vinanet

Aug 19, 2026
pulisher
Aug 19, 2026

Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 19, 2026
pulisher
Aug 18, 2026

Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus

Aug 18, 2026
pulisher
Aug 18, 2026

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn

Aug 18, 2026
pulisher
Aug 17, 2026

Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo

Aug 17, 2026
pulisher
Aug 17, 2026

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact - ChartMill

Aug 17, 2026
pulisher
Aug 17, 2026

Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25 - Moomoo

Aug 17, 2026
pulisher
Aug 17, 2026

Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 17, 2026
pulisher
Aug 16, 2026

Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat

Aug 16, 2026
pulisher
Aug 14, 2026

Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 14, 2026
pulisher
Aug 14, 2026

Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 14, 2026
pulisher
Aug 12, 2026

(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Aug 12, 2026
pulisher
Aug 11, 2026

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data - Sahm

Aug 11, 2026
pulisher
Aug 11, 2026

Pacira BioSciences, Inc. (PCRX) Investor Outlook: Navigating a 22.80% Potential Upside in Non-Opioid Solutions - DirectorsTalk Interviews

Aug 11, 2026
pulisher
Aug 10, 2026

J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Sell Rating, Maintains Target Price $23 - Moomoo

Aug 10, 2026
pulisher
Aug 10, 2026

Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat

Aug 10, 2026
pulisher
Aug 10, 2026

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy? - Yahoo Finance

Aug 10, 2026
pulisher
Aug 08, 2026

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform - Seeking Alpha

Aug 08, 2026
pulisher
Aug 08, 2026

Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat

Aug 08, 2026
pulisher
Aug 07, 2026

State Street Corporation (NYSE: STT) discloses 5.2% ownership in Pacira BioSciences - Stock Titan

Aug 07, 2026
pulisher
Aug 07, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 07, 2026
pulisher
Aug 06, 2026

Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK

Aug 06, 2026
pulisher
Aug 06, 2026

Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results - Moomoo

Aug 06, 2026
pulisher
Aug 06, 2026

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases - The Manila Times

Aug 06, 2026
pulisher
Aug 06, 2026

Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc. - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada

Aug 06, 2026
pulisher
Aug 06, 2026

One knee injection study followed pain and function for 2 years - Stock Titan

Aug 06, 2026
pulisher
Aug 05, 2026

Pacira BioSciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-08-05 - Seeking Alpha

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences (NASDAQ:PCRX) Trading Down 7.9%Should You Sell? - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Royal Bank Of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - marketbeat.com

Aug 05, 2026
pulisher
Aug 05, 2026

H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut - The Globe and Mail

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

PCRX Maintained by Needham -- Price Target Raised to $33.00 - GuruFocus

Aug 05, 2026
pulisher
Aug 05, 2026

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating - Moomoo

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $33.00 - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic Pivots - GuruFocus

Aug 05, 2026
pulisher
Aug 05, 2026

Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Aug 05, 2026
pulisher
Aug 05, 2026

PCRX SWOT Analysis: Strong Financial Recovery and Growth Potential Revealed in 10-Q Filing - GuruFocus

Aug 05, 2026
pulisher
Aug 04, 2026

Earnings call transcript: Pacira BioSciences posts solid Q2 2026 revenue beat - Investing.com

Aug 04, 2026
pulisher
Aug 04, 2026

Pacira BioSciences Q2 Earnings Call Highlights - TradingView

Aug 04, 2026
pulisher
Aug 04, 2026

Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B - GuruFocus

Aug 04, 2026

Pacira Biosciences Inc Stock (PCRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$48.87
price up icon 1.12%
RDY RDY
$12.22
price up icon 0.33%
$24.42
price up icon 1.88%
$153.04
price up icon 0.00%
$16.54
price up icon 1.35%
$512.88
price down icon 0.05%
Cap:     |  Volume (24h):